202
Participants
Start Date
May 26, 2015
Primary Completion Date
July 26, 2019
Study Completion Date
July 26, 2019
Selinexor
Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
Dexamethasone
20 mg was given with each dose of Selinexor.
Jules Bordet Institute, Brussels
NYU Perlmutter Cancer Center, New York
Mt Sinai NYC, New York
Columbia University, New York
National & Kapodistrain University of Athens School of Medicine, Alexandra Hospital, Athens
Roswell Park Cancer Institute, Buffalo
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Johns Hopkins Medicine, Baltimore
UNC-Chapel Hill, Chapel Hill
Emory University / Winship Cancer Institute, Atlanta
Northside Hospital, Atlanta
University of Florida Health Cancer Center- Shands Cancer Center Hospital, Gainesville
Sylvester, University of Miami, Miami
H. Lee Moffitt Cancer Center Research Institute, Tampa
University of Alabama, Birmingham
Vanderbilt University Ingram Cancer Center, Nashville
Norton Cancer Institute, Louisville
Nantes University Hospital Center, Nantes
Gabrail Cancer Center, Canton
Indiana University Simon Cancer Center, Indianapolis
University of Michigan, Ann Arbor
Karmanos Cancer Institute / Wayne State University, Detroit
University of Iowa Hospitals & Clinics, Iowa City
Brabois Adults Hospital, Nancy
Universitätsmedizin Mainz, Mainz
Mayo Clinic Rochester, Rochester
Claude Huriez Hospital, Department of Blood Diseases, Lille
University of Chicago Medicine, Chicago
Washington University St. Louis, St Louis
Universitätsklinikum des Saarlandes Klinik für Innere Medizin I, Homburg
South Lyon Hospital Center, Department of Clinical Hematology, Lyon
Universitätsklinikum Heidelberg Medizinische Klinik V, Heidelberg
Hopital Saint-Antoine, Service d´Hematologie Clinique et Therapie Cellulaire, Paris
La Pitie-Salpetriere University Hospital, Department of Clinical Hematology, Paris
Necker Children's Hospital, Paris
Baylor Sammons Cancer Center, Dallas
Mayo Clinic (AZ), Scottsdale
Jonnsson Comprehensive Cancer Center / University of Los Angeles, Los Angeles
City of Hope, Duarte
Kaiser Permanente- Hawaii, Honolulu
Swedish Cancer Institute, Seattle
Smilow Cancer Hospital, New Haven
Tufts Medical Center, Boston
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center / John Therurer Cancer Center, Hackensack
Valley Hospital, Paramus
Kaiser Permanente Northwest OR, Portland
University Hospital Krems, Department of Internal Medicine II, Krems
Salzburg Regional Hospital Müllner, Salzburg
Medical University Vienna, Department of Internal Medicine I, Vienna
ZNA Stuivenberg, Antwerp
General Hospital Saint-Jan, Bruges
University Hospital Ghent, Ghent
University Hospital Leuven, Campus Gasthuisberg, Leuven
University hospital of Tuebingen, Internal Medicine II, Tübingen
Med. Klinik und Poliklinik II Universitätsklinikum, Würzburg
UCL Saint-Luc, Brussels
UCL Mont-Godinne, Yvoir
BAG Oncology Gemeinschaftspraxis, Dresden
University Hospital Freiburg, Department of Internal Medicine I, Freiburg im Breisgau
Lead Sponsor
Karyopharm Therapeutics Inc
INDUSTRY